clinical study Archives | Be Korea-savvy
Helsinn Initiates Two New Global Phase III Studies with Anamorelin

Helsinn Initiates Two New Global Phase III Studies with Anamorelin

LUGANO, Switzerland, Mar. 7 (Korea Bizwire) - Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the first patient has now been dosed in the new global Phase III program to evaluate anamorelin for the treatment of weight loss and anorexia in patients with advanced NSCLC with cachexia. Cancer cachexia [...]

Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting

GERMANTOWN, Md., Dec. 5 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that additional safety, efficacy and tolerability data from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189 at 40 mg once daily (QD) and 40 mg twice daily (BID) compared to [...]

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 9 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the last patient has been enrolled in the Phase [...]

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 2 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the Company has accelerated the timelines [...]

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

TEL-AVIV, Israel and RALEIGH, N.C., Jul. 12 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the second independent Data and [...]

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

SAN DIEGO, Mar. 28 (Korea Bizwire) — Invivoscribe® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics®, and personalized molecular medicine®, reports that its next-generation sequencing (NGS) LymphoTrack® Assay kits are being used by its LabPMM® clinical laboratories, pharmaceutical [...]

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

TEL-AVIV, Israel, Mar. 21 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced dosing of the first patient in the open-label extension [...]

RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

TEL-AVIV, Israel, Feb. 21 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the last patient enrolled in the Phase III study with [...]

RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma

RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma

TEL-AVIV, Israel, Dec. 19 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the first patients have been screened and a first patient has been [...]

RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential of RHB-104 in Multiple Sclerosis

RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential of RHB-104 in Multiple Sclerosis

TEL-AVIV, Israel, Dec. 12 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the top-line final results from its CEASE-MS Phase IIa proof-of-concept (PoC) clinical study [...]